Ultivue
Latest round
- Series A
Last raised
- May 2023
Total raised
- $99M
Investors
- 10
About Ultivue
Ultivue, Inc.Founded in 2015 in Cambridge, US, Ultivue specializes in innovative biomarker analysis technologies. The company has undergone strategic advancements but operates independently without known subsidiaries. Key founders include David Walt, Peng Yin, and Ralf Jungmann, while Jacques Corriveau serves as CEO.Ultivue specializes in advanced biomarker assays and image informatics solutions, prominently featuring its flagship InSituPlex® technology. This proprietary platform enables researchers to conduct multiplex biomarker analysis with high sensitivity and specificity through the use of DNA barcoded antibodies that facilitate the visualization of multiple antigens in tissue samples. Ultivue's OmniVUE™ panels and U-VUE® custom biomarkers are integral for scientists involved in precision medicine research, supporting a range of applications from cancer therapy development to tissue microenvironment studies. The company's products are utilized by academic institutions, biotech firms, and pharmaceutical companies primarily in North America and Europe, fostering innovative approaches in translational research.Ultivue operates on a transactional model that encompasses both direct sales and partnerships within the life sciences sector. The company offers pre-optimized biomarker panels and customizable assay development services, which are typically sold as ready-to-use kits to research institutions and laboratories. Partnerships with leading biotech firms enhance the distribution of Ultivue's products, facilitating a streamlined path from research to application. The modular nature of the InSituPlex® technology, available in various panel configurations, allows clients to select products based on their specific research requirements.In October 2024, Ultivue, Inc., which will enable the combined entity to offer unified solutions in spatial multi-omics and drive future technology breakthroughs. This merger aligns with Ultivue's strategy to enhance its product offerings and expand its market reach. The company aims to solidify its presence in existing markets while exploring expansions into new geographic regions as it continues to innovate in biomarker technologies.
Who invested in Ultivue
10 investors across 5 rounds
See all investors in Ultivue
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ultivue
Who invested in Ultivue?
Ultivue has 10 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ultivue raised?
Ultivue has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Ultivue last raise money?
Ultivue's most recent round on record is a Series A, in May 2023.
What does Ultivue do?
Ultivue is a biotechnology company.
Where is Ultivue headquartered?
Ultivue is headquartered in Cambridge, US.
Which VCs invest in companies like Ultivue?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ultivue's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ultivue? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.